OBJECTIVE: To describe the safety and efficacy of very minimal fluence photodynamic therapy (PDT) for chronic central serous chorioretinopathy (CSC). DESIGN: Retrospective case series. PARTICIPANTS: Five patients with chronic CSC. Two had previously failed alternative therapies, and one was taking concomitant corticosteroids. METHODS: Patients were treated with very minimal fluence PDT (12 J/cm(2), 150 mW/cm(2), for 80 seconds). Median follow-up time after PDT was 100 days (range, 51 to 154). RESULTS: All patients experienced an improvement in visual acuity and symptoms, as well as complete resolution of subretinal fluid. CONCLUSIONS: Very minimal fluence PDT appears to be a safe and effective treatment for chronic CSC. Based on these preliminary findings, a randomized controlled trial is warranted.
OBJECTIVE: To describe the safety and efficacy of very minimal fluence photodynamic therapy (PDT) for chronic central serous chorioretinopathy (CSC). DESIGN: Retrospective case series. PARTICIPANTS: Five patients with chronic CSC. Two had previously failed alternative therapies, and one was taking concomitant corticosteroids. METHODS:Patients were treated with very minimal fluence PDT (12 J/cm(2), 150 mW/cm(2), for 80 seconds). Median follow-up time after PDT was 100 days (range, 51 to 154). RESULTS: All patients experienced an improvement in visual acuity and symptoms, as well as complete resolution of subretinal fluid. CONCLUSIONS: Very minimal fluence PDT appears to be a safe and effective treatment for chronic CSC. Based on these preliminary findings, a randomized controlled trial is warranted.